NovellusDx and Primetech Sign an Exclusive Dealer Agreement in Japan

NovellusDx and Primetech announce that Primetech will provide NovellusDx’ functional genomics assay “FACT – Functional Annotation for Cancer Treatment” as an exclusive dealer in Japan for the pre-clinical market with sales, marketing and research support / technical support in Japan.

“We are pleased to be represented by such a trusted and honorable name as Primetech,” said Haim Gil-Ad, NovellusDx CEO, “Japan is the first territory where we grant agent agreements. This echoes our strong belief that the Japanese oncology market is of the upmost importance.”

“Precision medicine is changing oncology worldwide,” said Ryosuke Ogihara, Primetech president, “optimizing targeted treatment strategy based on tumor molecular alteration is more efficacious than standard treatment based on tumor localization and being able to measure the activity of specific mutations and their response to drugs is revolutionary.”

“We are excited to offer NovellusDx’ functional oncology assay to our existing pharma and research center clients,” said Keiichi Teramoto, Director of Marketing, of Primetech. “The FACT system has a great ability to predict the clinical outcome of the patients in the complex real-life setting. Now we will be able to bring the system to our clients developing cancer drugs and mechanisms of action.”

“Today, genomic sequencing plays an ever-increasing role in cancer treatment, but the functional significance of most mutations found in a patient’s DNA is unknown and so is the effect drugs have on them,” said Michael Vidne CCO of NovellusDx. “Japan is a huge, advanced market with the top research centers and pharma companies operating here. It is an honor for us to be able and help them.”